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doi:10.1016/j.ejvs.2008.06.001Abstract In the absence of randomized trials, the optimal management of patients who pres-
ent with concomitant carotid and coronary artery disease remains an enduring controversy,
with much of the debate revolving around whether staged or synchronous carotid endarterec-
tomy (CEA) will reduce peri-operative morbidity and mortality after cardiac surgery. Although
encouraging results have been reported using either strategy, there remains no consensus as to
which is preferable. More recently, however, carotid artery angioplasty with stenting (CAS) has
emerged as a potential alternative to CEA. In ‘high-risk for CEA’ patients, CAS has shown com-
parable short and long-term outcome rates to CEA. Accordingly, CAS followed by cardiac sur-
gery could offer a less invasive (and safer) therapeutic option in cardiac patients. This paper
reviews the evidence to date supporting the use of CASþ CABG, while highlighting potential
situations where such a strategy might be harmful. In particular, it will focus on how the need
for dual antiplatelet therapy after CAS can be balanced with avoiding unnecessary bleeding
complications after cardiac surgery.
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ty for Vascular Surgery. PublisheIntroduction
The optimal management of patients with concomitant
carotid and coronary artery disease who are scheduled to
undergo coronary bypass (CABG) remains controversial. Thed by Elsevier Ltd. All rights reserved.
380 J. Van der Heyden et al.heterogeneity of this subset of patients who present with
generalized atherosclerosis (and the lack of high-quality
natural history data) is the key to understanding this
controversy.
The fact that candidates for cardiac surgery present
with varying degrees of cerebrovascular disease is not
surprising and, we would contend, differentiation between
neurologically symptomatic and asymptomatic patients is
unnecessary. Silent brain infarcts are a common finding on
magnetic resonance imaging (MRI) in neurologically asymp-
tomatic elderly patients. Breteler et al. reported that
white matter brain abnormalities on MRI were found in
nearly one-third of patients with a history of hypertension,
diabetes mellitus, peripheral vascular disease and myocar-
dial infarction.1 Consequently, it is our contention (though
not that of all observers) that the treatment of carotid dis-
ease prior to CABG should involve all patients, irrespective
of their neurological status. In practice, this implies equal
treatment for symptomatic and asymptomatic patients, dif-
fering only in the stenosis threshold for intervening.
The aetiology of peri-operative neurological events
during cardiac surgery is multifactorial. Although carotid
artery disease is an important factor, it is probably only
responsible for about 50% of post-CABG strokes,2 while
more than half of all territorial infarctions on computed to-
mography (CT) or at autopsy are not related to carotid dis-
ease alone.3Atherosclerosis of the ascending aorta can also
cause stroke due to macro-embolisation to the cerebral
vessels and the role of ascending aorta atherosclerosis still
needs to be evaluated. It has probably been seriously
underestimated. Notwithstanding differences of opinion
regarding the predominant cause of post-CABG stroke, hy-
poperfusion (due to a severely stenotic carotid artery) or
micro-embolisation (from an ulcerated carotid plaque) are
important aetiological mechanisms.4,5 Hypotension induced
ischaemic neurological injury during cardiopulmonary by-
pass is hard to avoid in patients with severe carotid steno-
sis. During cardiopulmonary bypass cerebral autoregulation
is severely impaired, making cerebral blood flow directly
proportional to cerebral perfusion pressure.5
Established Proof or Accumulated Facts
Despite the limited available evidence regarding the
benefit of prophylactic carotid revascularisation, many
cardiac surgery patients with advanced carotid and coro-
nary disease are currently treated with staged or synchro-
nous carotid/coronary interventions. The rationale being
that this strategy will reduce perioperative mortality and
neurological morbidity. However, the overall effectiveness
of this approach is ultimately dependent on the procedural
risk. If it is too high, it is unlikely to confer benefit.
In a recent systematic review and meta-analysis, Naylor
et al.6 observed a 10e12% cumulative risk of death, stroke
or myocardial infarction (MI) following staged or synchro-
nous operations and questioned whether these risks were
too high to confer any clinical benefit (compared with iso-
lated CABG) in patients who were predominantly neurolog-
ically asymptomatic. As a consequence, there has been
considerable interest in establishing whether CAS might
be a safer and better alternative. CAS is less-invasive, it
does not require a neck incision, it does not cause cranialnerve injury and it involves shorter hospital stays.7e9 In
studies of patients considered ‘high risk for CEA’, CAS was
considered at least ‘as good as’ CEA.7
The concept of performing CAS prior to cardiac surgery is
not novel, but relatively few studies have reported their
outcomes and several have shown conflicting results
(Table1). In favour of CASþ CABG were studies by Ziada,
Kovacic and van der Heyden.10e12 Ziada reported signifi-
cantly fewer adverse events in patients who underwent
CAS prior to cardiac surgery, despite a higher baseline risk
profile compared to those undergoing combined CEA and
CABG.10 Kovacic reported a death, stroke, or MI rate of
10% among 20 patients undergoing staged CAS-CABG.11
The largest series is by Van der Heyden where 356 patients
were evaluated regarding safety, procedural risk and dura-
bility.12 In this study, the death rate was 3.7%, while the
stroke rate and MI rates were 3.1% and 2.0% respectively.
Table 1 also details the rates of MI after CAS but before
CABG. The overall periprocedural MI rate of 2.0% is in con-
trast with observational studies of CEA and CABG, which
vary from 3.6% (synchronous) to 6.5% (staged).6 It should
also be borne in mind that a considerable number of pa-
tients undergo CABG plus valve replacement or major aortic
repair. McKhann et al. reported that these procedures incur
a peri-operative stroke rate of 7.9% (CABGþ valve) and
8.7% when aortic repair was included.13 This advocates
a progressive preoperative risk stratification and a dedi-
cated management by selecting the optimal treatment to
pursue the lowest complication rate. In these ‘high risk’
patients, CAS prior to cardiac surgery could prove to be
a valuable alternative to the surgical approach.14,15
By contrast, unfavourable results following staged
CASþ CABG procedures in 52 patients were reported by
Randall.16 Interestingly, the relative paucity of periproce-
dural neurological events after CAS was offset by a much
higher risk of death/stroke after CABG (19.2%). This was
attributed to a prolonged delay to performing CABG.Optimal Timing and Antiplatelet Therapy
Randall’s series exposed an important paradox regarding
how one had to balance the optimal (dual) antiplatelet
therapy required for CAS against not leaving the patient too
long before undergoing CABG (ie how long did the patient
have to be left on clopidogrel to minimise the risks of stent
thrombosis but avoid other haemorrhagic complications).
Platelet accumulation immediately after CAS and emboli-
zation to distal sites is an important cause of procedural
complications.
Antiplatelet therapy with clopidogrel is effective in
reducing stent thrombosis in patients undergoing CAS and
reduces the risk of vascular events in other arterial beds,
thereby expanding the benefits of antiplatelet therapy and
providing a rationale for long-term use.17 However, it is
well known that antiplatelet drugs also increase bleeding
complications during cardiac surgery and dual antiplatelet
regimes could greatly increase the risk of bleeding in the
perioperative period.18 Two trials comparing dual antipla-
telet regime versus aspirin alone during CAS have clearly
shown that dual antiplatelet therapy is necessary for
optimal outcomes.19,20 In the majority of patients, stent
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Staged Carotid Stenting prior to Cardiac Surgery 381endothelialization occurs between 28 and 96 days after
CAS.21,22 During this vulnerable time period, the exposed
metallic stent acts as a prothrombotic surface for platelet
activation.19 Not surprisingly, CAS advocates are very reluc-
tant to stop clopidogrel prematurely. Accordingly, some
sort of compromise is inevitable.
In practice, the delay between performing CAS and
cardiac surgery will inevitably be determined by the
urgency of the cardiac disease. Hemodynamic instability,
dynamic ST-T changes on electrocardiography, refractory
angina despite optimal medical therapy or severe left main
disease warrant immediate action. In those patients re-
quiring urgent cardiac surgery, there are three possible
options. First, CAS is perfomed using dual antiplatelet
therapy which is not then stopped prior to performing an
urgent CABG procedure (unlikely to find universal favour
with cardiac surgeons). Mendiz24 has reported a series of 30
patients undergoing ‘‘fast track’’ or ‘‘synchronous’’ CAS-
CABG, with no strokes or neurological deaths. Their prac-
tice was to perform CAS and then immediately transfer
the patient to the operating room. Aspirin and unfractio-
nated heparin were administrated during CAS and clopidog-
rel was started after CABG.24 Kramer et al. reported no
deaths or neurological events among 37 patients treated
with CAS who underwent CABG within 48 hours.25 In their
series, antithrombotic therapy during and after CAS con-
sisted of unfractionated heparin and the glycoprotein IIb/
IIIa receptor antagonist eptifibatide (continued 6 hours
before CABG). The third option is to consider combined
CEA and CABG.
If, however, the patient’s cardiac condition allowed
three weeks to elapse before CABG was scheduled, it is
our practice to perform CAS (with dual antiplatelet ther-
apy) and then stop the clopidogrel 7 days pre-CABG (aspirin
continued) before restarting the clopidogrel after recovery
from surgery.23 In our experience, no carotid-stent throm-
bosis or increased perioperative bleeding complications
have been observed and this may evolve to be the best
compromise in non-urgent patients. Ziada’s patients
received oral aspirin and clopidogrel before CAS and in 50
patients adjunctive glycoprotein IIb/IIIa platelet inhibition
was used. After discharge from CAS they were treated for
2 to 4 weeks with aspirin and clopidogrel. The latter was
stopped 1 week before surgery which was performed after
a median time of 40 days. In Kovacic’s population aspirin
and clopidogrel were commenced prior to cardiac surgery.
If possible, CABG was not scheduled within 4 weeks of ca-
rotid stenting. The mean interval between carotid stenting
to CABG was 69.6 39.6 days. Antiplatelet therapy was
ceased >3 days prior to cardiac surgery in 10/20 patients
and continued up to and including the day before surgery
in the remainder. In Randall’s study the routine use of
dual antiplatelet therapy before stent insertion was intro-
duced during the study period, with 82.7% of patients pre-
treated with combined aspirin and clopidogrel. The timing
of cardiac surgery after stenting was at the discretion of
the cardiac surgeon with no further detail mentioned. After
the introduction of routine use of clopidogrel in carotid
stenting, it was recommended that this was continued
for 14 days. Future antithrombotic therapy might involve
new generation thienopyridines, such as prasugrel and can-
grelor, which have a faster onset of action, as well as more
Van der Heyden et al.
Yes
Symptomatics: >70%
Asymptomatics: >90%
3-D cerebrovascular angiography
Symptomatics: >50%
Asymptomatics: >80%
Yes
Carotid angioplasty with stent implantation
No further action
is required
No
No
All patients who are scheduled to undergo Coronary and/or 
Aortic surgery (with or without valve repair/replacement)
SCREENING:
patient history, physical examination
No Aortic valve Stenosis
or Mitral valve Insufficiency
Yes
CAROTID BRUIT
DUPLEX
Aortic valve Stenosis
or Mitral valve Insufficiency
No
History of
Cerebral ischemic event
Yes No
Figure 1 Institutional guidelines for the screening of patients scheduled for cardiac surgery.
382 J. Van der Heyden et al.potent, and less variable, inhibition of platelet function
ex vivo.26
Case Selection
In Nieuwegein, all patients scheduled for cardiac surgery
are screened for carotid artery disease by means of history
and physical examination and selective Duplex ultrasound
according to institutional guidelines (see Fig. 1). A carotidartery stenosis is considered ‘‘significant’’ when a diameter
reduction of at least 70% is measured in symptomatic pa-
tients or more than 90% in asymptomatic patients. Patients
fulfilling these stenosis thresholds then undergo diagnostic
cervical-cerebral angiography which also includes intracra-
nial views to determine the patency and completeness of
the circle of Willis. Three-dimensional rotational angiogra-
phy is performed in order to obtain detailed information
about the target stenosis.27
Staged Carotid Stenting prior to Cardiac Surgery 383Significant carotid artery disease is defined as a target
lesion in the common carotid artery, internal carotid
artery, or at the bifurcation with a angiographic stenosis
severity of more than 50% of the luminal diameter in
symptomatic patients or >80% in those without symptoms
according to NASCET criteria.28,29 Patients are accepted
for CAS by a consensus decision involving a neurologist,
cardiovascular surgeon and interventional cardiologist.
When the aortic arch is markedly unfolded and peripheral
vascular disease or severe tortuosity makes any endovascu-
lar procedure more hazardous, the patient is referred for
combined CEA-CABG. Furthermore, patients with allergy
and/or insensitivity to acetylsalicylic acid, heparin, or
clopidogrel and severe renal insufficiency are also not
suited for CAS.
Procedural Complications
Whether or not the 3 % rule for isolated CEA can be
achieved in such a high risk population remains uncertain.
However, undertaking a CAS procedure with a 3%
complication rate in asymptomatic patients and <6% in
symptomatic patient, should remain the goal of all
interventionists.30,31 Patients with recent onset neurolog-
ical symptoms may pose an additional problem. They face
the highest risk of stroke in the first few weeks of the in-
dex event and CAS/CEA may have to be performed with
the acceptance that the procedural risk will be higher.32
Delaying the intervention might reduce the procedural
risk but it lessens the benefit of intervening because of
the number of strokes that happen whilst waiting.
Future perspectives
Ideally, a randomised trial would establish the roles of
medical therapy, CEA and CAS. Unfortunately, the target
population is too small. In a nationwide US survey, among
the population of patients undergoing CABG, those
undergoing combined CEA-CABG accounted for only 1.1%
in 1993 and 1.6% in 2002.33 Even lower was the proportion
of combined CEA-CABG procedures compared with CABG
in a recent Canadian survey (0.5%).34 Finally, high-volume
centers report between 13 and 30 combined surgical proce-
dures per year. Consequently, given the assumption of a
30-day death, stroke, or MI rate in the CEA-CABG group of
12% and a noninferiority boundary of 3%, such a study would
require an enrollment of 4000 patients to be adequately
powered.35 In the absence of such a trial, a realistic way
of improving the evidence would be to perform small, ran-
domized studies focusing on surrogate end points, such as
the occurrence of new lesions on MRI or measuring the
amount of microemboli detected on transcranial Doppler
during procedures.36
Conclusion
In the absence of evidence, the optimal revascularization
strategy for the heterogeneous group of patients with
concomitant coronary and carotid disease will have to be
decided on a case-by case basis by a multidisciplinary team
that includes neurologists, surgeons, and interventionists.This will take into account the comorbidities of the patient,
the degree of urgency of cardiac surgery, and local
expertise.
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